Evaluating thermogravimetric analysis for the measurement of drug loading in mesoporous silica nanoparticles (MSNs)

In this study, a thermogravimetric analysis (TGA) method for measuring the drug loading in mesoporous silica nanoparticles (MSNs) has been developed and evaluated in comparison with the drug loading quantification by high-performance liquid chromatography (HPLC). Indapamide was loaded into two different types of MSNs, namely Mobile Crystalline Material (MCM-41, pore size = 1.2 nm) and Santa Barbara Amorphous (SBA-15, pore size = 4.1 nm). Physical mixtures of the drug and silica gave a linear correlation between the observed and expected drug content for both TGA and HPLC, which were used for calibration purposes. The limit of detection (LOD) for the TGA method obtained from the physical mixture calibration curve was 0.77 % (w/w) and the r² value was 0.9936, whereas the HPLC had a LOD of 0.06 % (w/w) and an r² value of 0.9933. The sensitivity of the TGA method was well established using the drug loading studies, as it can detect the low loading of MCM-41 at 2.2 ± 0.21 % (w/w), compared to 5.1 ± 0.12 % (w/w) with the SBA-15. In all samples applied, the multiple comparison analysis showed an insignificant difference between the two methods (p > 0.05). The TGA data presented good evidence for using this technique as a sensitive, cost-effective, and low-variable quantitative analysis in the drug loading determination of the MSNs. TGA is not a selective method of quantification, but optimising the method using the pure and blank samples of MSNs and drug can significantly improve the sensitivity. This work provides a unique approach to apply TGA as a selective and more favourable method to characterise MSNs to do early formulation developments

Engineering of solidified glyburide nanocrystals for tablet formulation via loading of carriers: downstream processing, characterization, and bioavailability

Hany SM Ali,1,2 Ahmed F Hanafy,1,3 Abdulmalik Alqurshi1 1Department of Pharmaceutics and Pharmaceutical Technology, College of Pharmacy, Taibah University, Al-Madinah Al-Munawwarah, Saudi Arabia; 2Department of Pharmaceutics, Faculty of Pharmacy, Assiut University, Assiut, Egypt; 3Research and Development Department, Al Andalous Pharmaceutical Industries, Cairo, Egypt Introduction: Presenting poorly water-soluble drugs as nanoparticles has shown to be an effective technique in enhancing drug dissolution rate, intrinsic solubility, and thus oral bioavailability. Nevertheless, working with nanoparticles introduces many challenges, one of which is their physical instability. Formulating nanoparticles into a solid dosage form may overcome such challenges and thus unlock the potential benefits of nanosizing. Methods: The current work investigates the possibility of developing a novel solid dosage form, with enhanced dissolution rate, whereby nanocrystals (~400 nm) of the class II Biopharmaceutical Classification System drug, glyburide (GBD) were fabricated through combined precipitation and homogenization procedures. Using a novel, but scalable, spraying technique, GBD nanocrystals were loaded onto commonly used tablet fillers, water-soluble lactose monohydrate (LAC), and water insoluble microcrystalline cellulose (MCC). Conventional tableting processes were then used to convert the powders generated into a tablet dosage form. Results: Studies of redispersibility showed considerable preservation of size characteristics of GBD nanocrystals during downstream processing with redispersibility indices of 105 and 118 for GBD–LAC and GBD–MCC, respectively. Characterization by differential scanning calorimetry, powder X-ray diffraction, and scanning electron microscopy showed that the powders generated powders contained nanosized crystals of GBD which adhered to carrier surfaces. Powder flowability was characterized using Hausner ratio (HR) and Carr’s index (CI). GBD–LAC-loaded particles exhibited poor flowability with CI and HR of 37.5% and 1.60, respectively, whilst GBD–MCC particles showed a slightly improved flowability with CI and HR of 26.47% and 1.36, respectively. The novel tablet dosage form met US Pharmacopeia specifications, including drug content, hardness, and friability. Conclusion: Higher dissolution rates were observed from the nanocrystal-based tablets compared to the microsized and commercial drug formulations. Moreover, the novel nanocrystal tablet dosage forms showed enhanced in vivo performance with area under the plasma concentration–time curve in the first 24 hours values 1.97 and 2.24 times greater than that of marketed tablets. Keywords: glyburide, nanocrystals, downstream, tablet, bioavailability, solidification, redispersibilit

Evaluating thermogravimetric analysis for the measurement of drug loading in mesoporous silica nanoparticles (MSNs)

In this study, a thermogravimetric analysis (TGA) method for measuring the drug loading in mesoporous silica nanoparticles (MSNs) has been developed and evaluated in comparison with the drug loading quantification by high-performance liquid chromatography (HPLC). Indapamide was loaded into two different types of MSNs, namely Mobile Crystalline Material (MCM-41, pore size = 1.2 nm) and Santa Barbara Amorphous (SBA-15, pore size = 4.1 nm). Physical mixtures of the drug and silica gave a linear correlation between the observed and expected drug content for both TGA and HPLC, which were used for calibration purposes. The limit of detection (LOD) for the TGA method obtained from the physical mixture calibration curve was 0.77 % (w/w) and the r2 value was 0.9936, whereas the HPLC had a LOD of 0.06 % (w/w) and an r2 value of 0.9933. The sensitivity of the TGA method was well established using the drug loading studies, as it can detect the low loading of MCM-41 at 2.2 ± 0.21 % (w/w), compared to 5.1 ± 0.12 % (w/w) with the SBA-15. In all samples applied, the multiple comparison analysis showed an insignificant difference between the two methods (p &gt; 0.05). The TGA data presented good evidence for using this technique as a sensitive, cost-effective, and low-variable quantitative analysis in the drug loading determination of the MSNs. TGA is not a selective method of quantification, but optimising the method using the pure and blank samples of MSNs and drug can significantly improve the sensitivity. This work provides a unique approach to apply TGA as a selective and more favourable method to characterise MSNs to do early formulation developments.</p

Solid-state epimerisation and disproportionation of pilocarpine HCl: Why we need a 5-stage approach to validate melting point measurements for heat-sensitive drugs

Melting points for new drugs are reported in regulatory documents, e.g. investigational brochures, and frequently in published research; however, the authors do not typically consider that heat-induced degradation can affect the melting point measurement. Applying a single heating rate is not adequate, and thus many melting points in the literature and regulatory documentation are not valid. Our aim was to validate a five-stage approach for the melting point measurement of heat-sensitive drugs. These stages are; 1) observe melting; 2) record mass loss; 3) measure melting points at different heating rates; 4) characterise degradation and 5) test for potential isomerisation. Applying this approach to pilocarpine HCl illustrated the sensitivity of a melting point to thermal degradation. Due to salt disproportionation & loss of HCl gas, pilocarpine's melting point decreased by 14 °C when the heating rate was lowered from 20 to 1 °C/min. Epimerization occurred before melting was reached. Increasing the heating rate diminished disproportionation; however, this did not remove epimerization. Thus, the melting point of pilocarpine HCl of 205.5 ± 0.4 °C measured at 20 °C/min represents the melt of a racemic mixture containing inactive isopilocarpine. Heating above the melting point accelerated degradation, a rate of 5°C/min recovered just 38 ± 1% of pilocarpine. Such data predicted a shelf-life of 6.6years. Pilocarpine successfully validated the multistage approach by providing new knowledge concerning its thermal stability. Our 5-stage approach must be applied to all new drugs especially if their formulation requires heat. For example, thermal stability is an infrequently considered pre-requisite in the emerging field of 3D printing

Boosting Tadalafil Bioavailability via Sono-Assisted Nano-Emulsion-Based Oral Jellies: Box&ndash;Behnken Optimization and Assessment

Tadalafil (TAD) is a poorly soluble, phosphodiesterase inhibitor used to treat erectile dysfunction. The primary goal of this project was to prepare nano-emulsions using ultrasonic technology to address TAD bioavailability concerns. The Box&ndash;Behnken design was employed to find prominent correlations between factors impacting the sono-emulsification process. The emulsifier concentration, amplitude level, and ultrasonication time were the independent factors, whereas the average droplet size (ADS) and polydispersity index (PDI) were designated as the response variables. TAD-loaded nano-emulsions (93&ndash;289 nm) were generated and the emulsifier concentration showed a crucial role in directing emulsion droplet size. The model desirability function was utilized to optimize a nano-emulsion with a small ADS (99.67 &plusmn; 7.55 nm) and PDI (0.45 &plusmn; 0.04) by adjusting the emulsifiers concentration, amplitude level, and ultrasonication time at 9.85%, 33%, 49 s, respectively. The optimized nano-emulsions did not demonstrate any precipitation or phase separation after stability stress tests. TAD jellies were formulated based on the optimized nano-emulsion and subjected to in vitro evaluation for physical characteristics; TAD content, pH, spreadability, viscosity, syneresis, and taste-masking ability. An optimized nano-emulsion-based jelly (NEJ) formulation showed more than 96% drug dissolution in 30 min relative to 14% for the unprocessed TAD. In vivo assessment of NEJ in experimental rats demonstrated a significant enhancement (p &lt; 0.05) of TAD bioavailability with an AUC0&ndash;24h of 2045 &plusmn; 70.2 vs. 259.9 &plusmn; 17.7 ng&middot;h&middot;mL&minus;1 for the unprocessed TAD. Storage stability results revealed that NEJ remained stable with unremarkable changes in properties for 3 months. Overall, NEJ can be regarded as a successful therapeutic option for TAD administration with immediate-release properties and improved bioavailability

Tadalafil-Loaded Self-Nanoemulsifying Chewable Tablets for Improved Bioavailability: Design, In Vitro, and In Vivo Testing

This research aimed to develop innovative self-nanoemulsifying chewable tablets (SNECT) to increase oral bioavailability of tadalafil (TDL), a nearly insoluble phosphodiesterase-5 inhibitor. Cinnamon essential oil, PEG 40 hydrogenated castor oil (Cremophor&reg; RH 40), and polyethylene glycol 400 served as the oil, surfactant, and cosurfactant in the nanoemulsifying system, respectively. Primary liquid self-nanoemulsifying delivery systems (L-SNEDDS) were designed using phase diagrams and tested for dispersibility, droplet size, self-emulsifying capability, and thermodynamic stability. Adsorption on a carrier mix of silicon dioxide and microcrystalline cellulose was exploited to solidify the optimum L-SNEDDS formulation as self-nanoemulsifying granules (SNEG). Lack of crystalline TDL within the granules was verified by DSC and XRPD. SNEG were able to create a nanoemulsion instantaneously (165 nm), a little larger than the original nanoemulsion (159 nm). SNECT were fabricated by compressing SNEG with appropriate excipients. The obtained SNECT retained their quick dispersibility dissolving 84% of TDL within 30 min compared to only 18% dissolution from tablets of unprocessed TDL. A pharmacokinetic study in Sprague&ndash;Dawley rats showed a significant increase in Cmax (2.3-fold) and AUC0&ndash;24&nbsp;h (5.33-fold) of SNECT relative to the unprocessed TDL-tablet (p &lt; 0.05). The stability of TDL-SNECT was checked against dilutions with simulated GI fluids. In addition, accelerated stability tests were performed for three months at 40 &plusmn; 2 &deg;C and 75% relative humidity. Results revealed the absence of obvious changes in size, PDI, or other tablet parameters before and after testing. In conclusion, current findings illustrated effectiveness of SNECT to enhance TDL dissolution and bioavailability in addition to facilitating dose administration

Digital Image Disintegration Analysis:a Novel Quality Control Method for Fast Disintegrating Tablets

Measuring tablet disintegration is essential for quality control purposes; however, no established method adequately accounts for the timeframe or small volumes of the medium associated with the dissipation process for fast disintegrating tablets (FDTs) in the mouth. We hypothesised that digital imaging to measure disintegration in a low volume of the medium might discriminate between different types of FTD formulation. A digital image disintegration analysis (DIDA) was designed to measure tablet disintegration in 0.05–0.7 mL of medium. A temperature-controlled black vessel was 3D-printed to match the dimensions of each tablet under investigation. An overhead camera recorded the mean grey value of the tablet as a measure of the percentage of the formulation which remained intact as a function of time. Imodium Instants, Nurofen Meltlets and a developmental freeze-dried pilocarpine formulation were investigated. The imaging approach proved effective in discriminating the disintegration of different tablets (p < 0.05). For example, 10 s after 0.7 mL of a saliva simulant was applied, 2.0 ± 0.3% of the new pilocarpine tablet remained, whereas at the same time point, 22 ± 9% of the Imodium Instants had not undergone disintegration (temperature within the vessel was 37 ± 0.5°C). Nurofen Meltlets were observed to swell and showed a percentage recovery of 120.7 ± 2.4% and 135.0 ± 6.1% when 0.05 mL and 0.7 mL volumes were used, respectively. Thus, the new digital image disintegration analysis, DIDA, reported here effectively evaluated fast disintegrating tablets and has the potential as a quality control method for such formulations. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1208/s12249-021-02080-0